Shionogi & Co., Ltd.
Basic information
- Head office
- 5-54, Doshomachi 5-chome, Kita-ku, Osaka 530-0011, Grand Green Osaka South Building Park Tower
- Chief executive
- Shunichi Tanaka
- Capital
- 21,279,742,717 (212 100 million)
- Employees (non-consolidated)
- 2,129 people
- Employees (consolidated)
- 4,959 people
- Start date
- 1948-01-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Shionogi Canada Inc. | ||||||||
| Stream-I Corporation | ||||||||
| トリイ日本橋 | ||||||||
|
|
Network
History
Founder Saburo Shiono, established the drug wholesaler Shiono Saburo Store in Osaka Dojima-cho, selling traditional Chinese and Japanese medicines![]()
Shiro Yoshi Shiono founded the drug wholesaler "Shiono Yoshi Saburo Shoten" at 3-12 Dojima-machi, Osaka.![]()
On March 17, 1878, on his 24th birthday, he became independent and founded the drugstore "Shiono Giyoshi Saburo Shoten" at 3-12 Doshomachi, Osaka.![]()
Initially handled mainly Japanese and Chinese medicines, but in 1886, eight years after opening, Western medicine began to spread widely, and imported Western medicines sales started.![]()
Second son Chojuro began trial manufacturing of antacid and commercialized the gastrointestinal antacid "Antachidin".![]()
Manufacture and sale of the first original new drug antacid "Antachidin": Trademark registration of the balance weight mark.![]()
Following the graduation of Giyosaburo's second son, Chojuro, from the Department of Pharmacy at Tokyo Imperial University, SHIONOGI began full-scale pharmaceutical research. During this period, the pharmacist managing Shiono Giyoshi Saburo Shoten heard from a pediatrician at Osaka Medical College (now Osaka University School of Medicine) that prescriptions for antacids were written in German medical books. Chojuro then started trial manufacturing of the antacid and succeeded in productization. This gastrointestinal antacid "Antachiden" became the first new drug developed in-house by Shiono Giyoshi Saburo Shoten.![]()
The symbol of SHIONOGI is derived from the "counterweight" used when weighing medicines on a balance. The counterweight symbolizes "accuracy," "honesty," and "trust," representing SHIONOGI's constant pursuit of precision.![]()
Built a pharmaceutical factory "Shiono Pharmaceutical Co., Ltd." in Nishinari District, Osaka Prefecture, and fully launched the pharmaceutical business.![]()
Giyosaburo aimed to develop the business of new drug manufacturing seriously, and built a pharmaceutical factory "Shiono Seiyakujo" in Nishinari District, Osaka Prefecture (now Fukushima Ward, Osaka City).![]()
Shiono Saburo Store merged with Shiono Pharmaceutical Plant, reorganized into Shiono Pharmaceutical Co., Ltd.![]()
Merged Shiono Yoshiro Shop and Shiono Pharmaceutical Co., Ltd., and established "Shiono Yoshiro Corporation".![]()
In 1919, aiming for further development of SHIONOGI, Giyosaburo's eldest son, Shotaro, managed the drugstore and Shiono Giyoshi Saburo Shoten, and his second son, Chojuro, managed the pharmaceutical business and Shiono Seiyakujo, merged to establish "Shiono Giyoshi Shoten Co., Ltd."![]()
Kusatsu Factory (Amagasaki City, Hyogo Prefecture) was established, with a laboratory set up inside the factory![]()
Launched the Kuse Factory (Amagasaki City, Hyogo Prefecture) (currently Kuse Business Office), and established a laboratory within the factory.![]()
In 1943, the company name was changed to "Shiono Giyoshi Pharmaceutical Co., Ltd." to clearly indicate the focus on pharmaceuticals.![]()
Due to post-war inflation and economic turmoil, management deteriorated, and Gizoro indicated policies for management improvement.![]()
After the war, rapid inflation, soaring prices, and societal chaos led to the freezing of corporate deposits and termination of wartime compensation, causing SHIONOGI to nearly go bankrupt and fall into its worst management condition since its founding.![]()
Inherited a corporate culture that emphasizes manufacturing better products and technological development.![]()
Constructed Central Research Institute (Fukushima-ku, Osaka) (now consolidated into Pharmaceutical Research Center)![]()
Established Animal Pharmaceuticals Department (transferred in 2002), Plant Pharmaceuticals Department (transferred in 2001), began operations of Clinical Testing Laboratory (transferred in 2002), established Taiwan Shionogi Pharmaceutical Co., Ltd.![]()
Established the Animal Medicine Department (transferred in 2002), Plant Medicine Department (transferred in 2001), and started operations of the Clinical Laboratory (transferred in 2002): Established Taiwan Shiono Yoshiro Pharmaceutical Co., Ltd.![]()
Constructed Shionogi Shibuya Building (Shibuya-ku, Tokyo), built New Drug Research Institute (Toyonaka City, Osaka Prefecture) (now Pharmaceutical Research Center)![]()
Built Shiono Yoshi Shibuya Building (Shibuya-ku, Tokyo): Built New Drug Research Institute (Toyonaka City, Osaka) (currently Medical Research Center).![]()
Constructed Medical Science Research Institute (within Settsu Factory grounds) (now consolidated into Pharmaceutical Research Center), launched Furmarin![]()
Construction of the Medical Science Research Institute (within the Settsu Factory site) (now consolidated into the Pharmaceutical Research Center): Launch of Oxas Cefem Antibiotic "Furmarin"![]()
Established Shionogi General Service Co., Ltd. (now Shionogi Business Partner Co., Ltd.), acquired capsule business from Eli Lilly (sold in 2005)![]()
Establishment of Shionogi General Service Co., Ltd. (now Shionogi Business Partner Co., Ltd.): Acquisition of capsule business from Eli Lilly & Co. (sold in 2005)![]()
Formulated Shionogi Action Charter (revised in 2012), launched Omori Pharmaceutical Co., Ltd. (sold in 2002), established Bushu Pharmaceutical Co., Ltd. (sold in 2010)![]()
Formulation of Shionogi Action Charter (revised in 2012): Establishment of Omori Pharmaceutical Co., Ltd. (sold in 2002): Establishment of Bushu Pharmaceutical Co., Ltd. (sold in 2010)![]()
Transferred plant medicines, animal medicines, and pharmaceutical wholesale to other companies, consolidating into the pharmaceutical business.![]()
Established Shionogi USA, Inc., and Shionogi-GlaxoSmithKline Pharmaceuticals LLC, and began joint research on HIV treatments![]()
Establishment of Shionogi USA, Inc. (now Shionogi Inc.): Overseas JV: Establishment of Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC), initiating joint research and development of HIV infection drugs![]()
Start of the Second Mid-term Management Plan, launch of the high cholesterol treatment drug "Crestor", launch of the carbapenem antibiotic "Fynvax"![]()
Start of the second medium-term management plan: Launch of cholesterol-lowering drug "Crestor": Launch of carbapenem antibiotic "Finibax"![]()
Acquired US-based Sciele Pharma, Inc., established a joint research facility with Hokkaido University, Shionogi Drug Discovery Innovation Center, launched the hypertension treatment drug "Irbetan", launched Diferrin, Pirespa![]()
Acquisition of US-based Sciele Pharma, Inc. (now Shionogi Inc.): Opening of joint research facility with Hokkaido University, Shionogi Drug Discovery Innovation Center: Launch of antihypertensive drug "Irbetan": Launch of acne treatment drug "Diferin": Launch of idiopathic pulmonary fibrosis drug "Pirespa"![]()
Start of the Third Mid-term Management Plan, established Shionogi Techno-Advance Research Inc., opened PET Center with Osaka University, launched the anti-influenza drug "Lapiakta", launched the antidepressant "Simbalta"![]()
Start of the third medium-term management plan: Establishment of Shionogi Techno Advance Research Co., Ltd.: Opening of Osaka University Graduate School of Medicine PET Molecular Imaging Center: Launch of anti-influenza drug "Lapiatra": Launch of antidepressant "Simbalta"![]()
Acquisition of Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited: Construction of new research building SPRC4 within the Pharmaceutical Research Center (SPRC), consolidating drug discovery research functions![]()
Established Shionogi Limited (UK), launched HIV treatment drug "Ofikast", launched hypertension treatment drug "Aimix", contracted with Vibe Healthcare![]()
Establishment of European subsidiary Shionogi Limited (UK): Signing of new framework agreement with Veev Healthcare for HIV infection drugs: Launch of cancer pain relief injection "OkiFast": Launch of antihypertensive drug "Aimix"![]()
Established Beijing Shionogi Pharmaceutical Technology Co., Ltd. and Shionogi Singapore Pte. Ltd., changed royalty contract for Crestor, launched postmenopausal vaginal atrophy treatment "Osphena" in the US, launched Itratra![]()
Establishment of Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China): Establishment of Shionogi Singapore Pte. Ltd.: Modification of royalty agreement for Crestor with AstraZeneca: Launch of postmenopausal vaginal atrophy treatment "Osphena" in the US: Launch of antihypertensive drug "Ilutra"![]()
Start of the medium-term management plan "Shionogi Growth Strategy 2020 (SGS2020)": Launch of HIV treatment drug "Tebikei"![]()
Formulated a mid-term management plan aiming for growth as a drug discovery-oriented pharmaceutical company, with ROE as an indicator.![]()
Launched HIV treatment drug "Trimek", allergen immunotherapy drug "Asitea", thrombocytopenia treatment drug "Mulpeta"![]()
Launch of HIV treatment drug "Triumeq": Launch of allergen immunotherapy drug "Asitea": Launch of thrombocytopenia treatment drug "Mulpeta"![]()
Update of the medium-term management plan "SGS2020": Establishment of Shionogi Healthcare Co., Ltd.: Launch of cholesterol-lowering drug "Crestor OD Tablets"![]()
Established domestic group companies, launched Mesapain, Inchtunib, Symproic, Swinproic, OxyContin TR tablets![]()
Establishment of domestic group companies: Shionogi Career Development Center Co., Ltd., Shionogi Digital Science Co., Ltd., Shionogi Business Partner Co., Ltd., Shionogi Pharmacovigilance Center Co., Ltd., Shionogi Marketing Solutions Co., Ltd.: Launch of cancer pain relief agent "Mesapain": Launch of attention deficit/hyperactivity disorder treatment "Inchunibu": Launch of opioid-induced constipation treatment "Symproic" in the US: Launch of opioid-induced constipation treatment "Swinproic": Launch of sustained cancer pain treatment "OxyContin TR Tablets"![]()
Established Shionogi Pharma, established Shionogi B.V. in Europe, launched "Zofluza", launched "Mulpleta" in the US, launched "Jalka"![]()
Establishment of Shionogi Pharma Co., Ltd.: Establishment of European subsidiary Shionogi B.V.: Launch of anti-influenza drug "Zofluza": Launch of thrombocytopenia treatment "Mulpleta" in the US: Launch of anti-HIV drug "Jarlca"![]()
Established joint venture "Stream-I Co., Ltd." with M3, made UMN Pharma a subsidiary, opened training center in Amagasaki City, launched "Rizmoic" in Taiwan, launched "Shufu Xiao" in Taiwan, launched "Vibance"![]()
Establishment of joint venture with M3 Corporation "Stream Eye Co., Ltd.": Consolidation of UMN Pharma as a subsidiary: Opening of Shionogi Education and Training Center in Amagasaki City: Launch of opioid-induced constipation treatment "Rizmoic" in Europe: Launch of anti-influenza drug "Shufu Xie" in Taiwan: Launch of attention deficit/hyperactivity disorder treatment "Vibance"![]()
Start of Shionogi Transformation Strategy 2030 (STS2030), established joint venture with Ping An of China, made Tetra a subsidiary, made Nagase Pharmaceuticals a subsidiary, launched "Fetroja" and "Fetcroja" in the US and Europe![]()
Start of the medium-term management plan "Shionogi Transformation Strategy 2030 (STS2030)": Establishment of joint venture with Ping An Insurance "Ping An Shionogi Co., Ltd.": Full acquisition of Tetra Corporation in the US: Acquisition of Nagase Pharmaceuticals by Shionogi Pharma: Launch of Gram-negative bacterial infection treatment "Fetroja" in the US: Launch of Gram-negative bacterial infection treatment "Fetcroja" in Europe![]()
Start of sewage epidemiology survey service for COVID-19: Opioid-induced constipation treatment drug "Swinproik" launched in Taiwan![]()
Established AdvanSentinel Inc., established "Shionogi Infectious Disease Research Promotion Foundation", launched "Zokova"![]()
News
There is no news.
Public records
National Tax Agency basic information9120001077430
- Trade name
- 塩野義製薬株式会社
- Trade name (kana)
- シオノギセイヤク
- Name in English
- Corporation type
- 301
- Address
- 〒541-0045 大阪府大阪市中央区道修町3丁目1番8号
- Postal code
- 5410045
- Prefecture code
- 27
- City code
- 128
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2019-10-08
- Change date
- 2019-10-01
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- 令和1年10月1日大阪市中央区道修町三丁目1番8号株式会社ピオニエ(1120001192963)を合併
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 71
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 4414321
METI gBizINFO9120001077430
- Corporate number
- 9120001077430
- Trade name
- 塩野義製薬株式会社
- Trade name (kana)
- シオノギセイヤク
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 大阪府大阪市中央区道修町3丁目1番8号
- Postal code
- 5410045
- Prefecture
- 大阪府
- Prefecture code
- 27
- City or district
- 大阪市中央区
- City code
- 128
- Street address
- 道修町3丁目1番8号
- Organisation type
- 301
- Processing type
- 71
- Correction type
- 0
- Status
- Representative
- 代表取締役会長兼社長 CEO 手代木 功
- Capital
- 21279000000
- Employees
- 2808
- Employees (male)
- 2086
- Employees (female)
- 722
- Business summary
- 医薬品、診断薬などの製造・販売
- Website URL
- http://www.shionogi.co.jp/index.html
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2019-10-08
- Key information
- 9120001077430